These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17140357)

  • 1. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.
    Waters V; Ratjen F
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):807-19. PubMed ID: 17140357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on antibiotics for infection control in cystic fibrosis.
    Kirkby S; Novak K; McCoy K
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):967-80. PubMed ID: 19803706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
    Conway SP; Brownlee KG; Denton M; Peckham DG
    Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging and unusual gram-negative infections in cystic fibrosis.
    Davies JC; Rubin BK
    Semin Respir Crit Care Med; 2007 Jun; 28(3):312-21. PubMed ID: 17562501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenging and emerging pathogens in cystic fibrosis.
    de Vrankrijker AM; Wolfs TF; van der Ent CK
    Paediatr Respir Rev; 2010 Dec; 11(4):246-54. PubMed ID: 21109184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis.
    Sibley CD; Parkins MD; Rabin HR; Surette MG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):787-94. PubMed ID: 19649923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiology of airway disease in a cohort of patients with cystic fibrosis.
    Lambiase A; Raia V; Del Pezzo M; Sepe A; Carnovale V; Rossano F
    BMC Infect Dis; 2006 Jan; 6():4. PubMed ID: 16405721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
    Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA
    Ann Am Thorac Soc; 2014 Sep; 11(7):1120-9. PubMed ID: 25102221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas aeruginosa and Burkholderia cepacia cannot be detected by PCR in the breath condensate of patients with cystic fibrosis.
    Vogelberg C; Hirsch T; Rösen-Wolff A; Kerkmann ML; Leupold W
    Pediatr Pulmonol; 2003 Oct; 36(4):348-52. PubMed ID: 12950050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
    Coman G; Petraru E; Dahorea C; Anton DT
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
    Murray TS; Stanley G; Koff JL
    Infect Dis Clin North Am; 2024 Mar; 38(1):149-162. PubMed ID: 38280761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-adherence activity and antimicrobial durability of anti-infective-coated catheters against multidrug-resistant bacteria.
    Raad I; Reitzel R; Jiang Y; Chemaly RF; Dvorak T; Hachem R
    J Antimicrob Chemother; 2008 Oct; 62(4):746-50. PubMed ID: 18653489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibiotic treatment of cystic fibrosis].
    de Montalembert M; Berche P; Lenoir G
    Ann Pediatr (Paris); 1991 Oct; 38(8):523-8. PubMed ID: 1746849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis.
    Stone A; Saiman L
    Curr Opin Pulm Med; 2007 Nov; 13(6):515-21. PubMed ID: 17901758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis].
    Girón RM; Buendía B; Pinedo C; Casanova A; Hoyos N; Ancochea J
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):85-8. PubMed ID: 19254640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial peptide therapeutics for cystic fibrosis.
    Zhang L; Parente J; Harris SM; Woods DE; Hancock RE; Falla TJ
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2921-7. PubMed ID: 15980369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of infection control policies for patients with cystic fibrosis in the United States.
    Zhou J; Garber E; Saiman L
    Am J Infect Control; 2008 Apr; 36(3):220-2. PubMed ID: 18371519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bacterial infections and resistance to antibiotics in cystic fibrosis].
    Taccetti G; Repetto T; Procopio E; Marianelli L; Campana S
    Pediatr Med Chir; 1999; 21(5 Suppl):213-8. PubMed ID: 10963010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial overview: clinical utility of synergy testing for multidrug resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Middleton PG
    Paediatr Respir Rev; 2007 Sep; 8(3):262-3, quiz 263-4. PubMed ID: 17868925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.